Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of$410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between$640 million to $670 million, Crysvita revenue of$460 million to $480 million, and Dojolvi revenue of$90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare a ...